Skip to main
ROIV
ROIV logo

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences Ltd's product brepocitinib (brepo) is positioned to capture a significant market opportunity, offering a convenient once-daily dosing regimen that stands in contrast to the cumbersome intravenous immunoglobulin (IVIg) therapy, which has approximately $500 million in global sales. Brepo's clinical trials underscore its efficacy, demonstrated by a mean total improvement score (TIS) of 46.5, indicating a substantial therapeutic benefit that meets high expectations from investors and key opinion leaders. The strong performance of brepo and its potential market application enhances Roivant Sciences's overall growth prospects, contributing to a positive outlook for the company's stock.

Bears say

Roivant Sciences Ltd has experienced significant setbacks in its clinical development portfolio, particularly with the failure of key assets such as IMVT and brepocitinib in various therapeutic areas. These failures raise concerns about the company's ability to successfully advance its drug candidates, potentially jeopardizing future revenue streams. Consequently, the frequent clinical trial failures indicate a challenging path ahead, which could negatively impact investor confidence and overall market performance.

ROIV has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 8 analysts, ROIV has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.